2977results about "Hybrid immunoglobulins" patented technology

The present invention provides a combination of (i) an immune checkpoint modulator and (ii) a T-cell redirecting multifunctional antibody, or an antigen binding fragment thereof, for use in therapeutic treatment of a cancer disease. The T-cell redirecting multifunctional antibody comprises (a) a specificity against a T cell surface antigen; (b) a specificity against a cancer- and / or tumor-associated antigen; and (c) a binding site for human FcγRI, FcγRIIa and / or FcγRIII, wherein the antibody, or the antigen binding fragment thereof, binds with a higher affinity to human FcγRI, FcγRIIa and / or FcγRIII than to human FcγRIIb.

The invention relates to an anti-CD3 nano antibody, an anti-CD38 antibody and a bispecific antibody containing the anti-CD3 nano antibody and the anti-CD38 antibody. According to the invention, an anti-CD3 nano antibody and an anti-CD38 monoclonal antibody are excavated and prepared, humanized design is carried out to obtain antibodies with high affinity and specificity, and different configurations of bispecific T cell conjugation antibodies targeting CD3 and CD38 are further designed, so that the CD3 and CD38 dual-specificity T cell conjugation antibodies are obtained. The antigen binding activity, the T cell-mediated tumor cell killing effect and the T cell proliferation and activation function of the antibody are systematically evaluated in vitro, and experimental results show that the T cell conjugation antibody can effectively recruit and activate T cells and has a remarkable killing effect on CD38 positive tumor cells, and it is further verified that the antibody has remarkable in-vivo anti-tumor activity and has a good application prospect. Therefore, the polypeptide has high affinity, good pharmacological characteristics and development potential.

This invention provides a tetrahedral antibody comprising a first, second, third, and fourth domain, wherein the first and second domains are Fab or Fc domains; wherein each of the first and second domains comprise a first polypeptide chain comprising a first N-terminus of the domain, and a second polypeptide chain comprising a second N-terminus of the domain; wherein the first N-terminus of the first domain and the first N-terminus of the second domain are joined to each other by a non-peptidyl linkage, which can be a covalent linkage or a non-covalent linkage between first and second dimerizing polypeptides attached to the first N-termini of the first and second domains, respectively; and wherein the third and fourth domains are attached at their respective C-termini to the second N-termini of the first and second domains, respectively, or the N-termini of the first and second dimerizing polypeptides.

Provided are a fusion protein (for example, in the form of a bispecific antibody) binding to CD235a and CD3, a preparation method therefor, and a related use thereof.

The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.

The invention discloses an anti-CLDN6 nano antibody and related application thereof, and relates to the field of antibodies. The invention provides an anti-CLDN6 nano antibody, which comprises HCDR1, HCDR2 and HCDR3 in a heavy chain variable region of which the amino acid sequence is as shown in SEQ ID NO: 4, the nano antibody has excellent antigen binding activity, high specificity and good affinity, has relatively strong killing activity on cells with high expression of CLDN6, and can be used for preparing anti-CLDN6 drugs. The requirements of CLDN6 positive tumor immunotherapy on efficient, specific and high-penetrability antibody molecules are met, and a new strategy and means are provided for tumor therapy.

The invention belongs to the field of biomedical detection, and particularly relates to a protein chip, a detection kit based on a polypeptide coding microarray chip and application of the detection kit. According to the protein chip provided by the invention, an antibody and a bispecific antibody of corresponding indexes can be added into a treating fluid according to detection requirements, the antibody and the bispecific antibody are combined with the chip in a manner of polypeptide specific recognition after being subjected to antigen specific recognition respectively, and joint detection of different antigen combinations and detection of a single index are carried out. By utilizing the polypeptide sample application chip and the antigen and antibody combined bispecific antibody provided by the invention, the universality of the chip in use, the high efficiency of detection and the low cost can be remarkably improved.

The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.

Provided are a method and system for enriching natural killer (NK) cells in a blood sample.

The invention discloses a cell membrane protein replacement type oncolytic virus vector and application thereof. The cell membrane protein replacement type oncolytic virus vector is rhabdoviridae virus, and a nucleotide sequence for coding G protein in a genome of the rhabdoviridae virus is replaced by a nucleotide sequence for coding an antibody and a nucleotide sequence for coding a spike protein truncation of coronavirus. The invention also discloses a construction method of the cell membrane protein replacement type oncolytic virus vector for expressing the antibody, the non-replicated virus vector is used for expressing the antibody sequence for the first time, and meanwhile, the novel coronavirus cell membrane protein is embedded into the virus surface, so that the cell membrane protein replacement type oncolytic virus vector can be rapidly produced in a suspension cell in a large scale; through removal of virus cell membrane protein genes, the virus cell membrane protein genes cannot be continuously replicated in vivo, so that the safety of the virus cell membrane protein genes is ensured, the tumor immunosuppression condition is improved, and an organism can be stimulated to generate a neutralizing antibody for resisting new coronavirus while tumor cells are killed.

The present invention provides methods and compositions for treating cancer and / or autoimmune diseases by modulating the expression and / or activity of IGSF8 and its binding ligand. Pharmaceutical compositions include, but are not limited to, antibodies that specifically bind to human IGSF8 and have the activity of inhibiting IGSF8-mediated immunosuppression in a subject in need thereof. Pharmaceutical compositions may include, but are not limited to, antibodies that specifically bind to human IGSF8 and have the activity of inhibiting IGSF8-mediated immunosuppression in a subject in need thereof.

Antibodies, antigen-binding proteins and Fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain Fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric Fc-containing antibodies, antigen-binding proteins and Fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric Fc-containing proteins are provided.

Described herein are antibodies, or antigen binding fragments thereof, that bind thymic stromal lymphopoietin (TSLP) and OX40L in combination and methods of use thereof. In certain aspects, described herein are methods of inhibiting OX40L and TSLP biological activity. In certain aspects, described herein are pharmaceutical compositions comprising the anti-TSLP and anti-OX40L antibodies, or antigen binding fragments thereof. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder associated with elevated levels of TSLP and / or OX40L.

The invention discloses a bispecific antibody which comprises a first protein functional region targeting CD30 and a second protein functional region targeting CD16a, the first protein functional region comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3. The invention also discloses nucleic acid for coding the antibody, a recombinant expression vector, a transformant, a preparation method of the antibody, an antibody drug conjugate, a pharmaceutical composition or a kit containing the antibody drug conjugate, and applications of the nucleic acid, the recombinant expression vector and the transformant in preparation of drugs for preventing and / or treating tumors. The bispecific antibody provided by the invention can effectively activate the NK cells and can effectively target human tumor cell related antigen CD30 protein, mediate the killing activity of the NK cells to target cells, and induce and further enhance the tumor inhibition effect of the NK cells to tumor cells.

The invention belongs to the technical field of biology, and particularly relates to an anti-porcine reproductive and respiratory syndrome virus antibody or an antigen binding fragment thereof and application thereof. The antibody or the antigen binding fragment thereof can specifically recognize and bind the porcine reproductive and respiratory syndrome virus or the GP4 protein thereof, and has good affinity with the porcine reproductive and respiratory syndrome virus or the GP4 protein thereof; the compound can be used for preparing products for diagnosing, preventing and / or treating porcine reproductive and respiratory syndrome virus infection or diseases caused by porcine reproductive and respiratory syndrome virus infection, detecting existence or level of porcine reproductive and respiratory syndrome virus or GP4 protein thereof in a sample or screening drugs for preventing and / or treating porcine reproductive and respiratory syndrome virus infection or diseases caused by porcine reproductive and respiratory syndrome virus infection.

The invention provides a TF and Her2 targeting bispecific antibody coupling drug as well as a preparation method and application thereof, and belongs to the technical field of biological drug preparation. The bispecific antibody provided by the invention can target TF and / or Her2 antigens in tumor cells, and has the advantages of high stability, easiness in expression, purification and coupling and the like. The bispecific antibody can be specifically combined with a tumor surface antigen and internalized into tumor cells, so that the tumor cells can be specifically killed. The bispecific antibody coupling drug prepared on the basis of the bispecific antibody has a good tumor inhibition effect in a cell model and an animal model, is nontoxic and harmless to animals, and has an excellent cancer treatment potential.

Provided are a therapeutic anti-IGF-1R and anti-TSHR bispecific antibody and a use thereof. Specifically disclosed are a single-domain antibody against IGF-1R, a bispecific antibody against IGF-1R and TSHR, a nucleic acid encoding the single-domain antibody or the bispecific antibody, a vector comprising the nucleic acid, and a host cell comprising the nucleic acid or the vector. Also provided are a pharmaceutical composition and conjugate or immune fusion comprising the antibody, and a treatment method using the antibody.

The subject matter described here relates to anti-PD-1 x anti-IL-25 bispecific antibodies. In certain embodiments the bispecific antibody is used for the treatment or prevention of cancer. In certain embodiments the bispecific antibody is used for the treatment or prevention of breast cancer. In some embodiments, the bispecific antibody limits immune related adverse events.

The invention relates to a VHH targeting VEGF, a PD-1 and VEGF targeting bispecific antibody developed based on the VHH, and an application of the bispecific antibody. The VHH is high in stability and has various excellent effects of being easy to express and purify and the like. The constructed bispecific antibody targeting PD-1 and VEGF is high in stability, can be enriched in a tumor area with high expression of VEGF in a targeted manner, has good drug effect and safety, and has excellent treatment potential.

An anti-CTLA4 (cytotoxic T lymphocyte associated antigen 4) and anti-PD-1 (programmed cell death 1) bifunctional antibody. a pharmaceutical composition thereof and use thereof. Particularly, the anti-CLTA4 and anti-PD-1 bifunctional antibody comprises a first protein functional domain that targets PD-1 and a second protein functional domain that targets CTLA-4. The bifunctional antibody can bind to CTLA-4 and PD-1 specifically, relieve immunosuppression of CTLA4 and PD-1 on an organism specifically, activate T lymphocytes, and thus has good application prospects.

To provide IL2 engrafted into CDR sequences of an antibody having preferred therapeutic profiles over molecules known and used in the clinic.SOLUTION: An antibody cytokine engrafted protein comprises: (a) an IgG class heavy chain comprising an IgG class heavy chain variable region (VH), comprising Complementarity Determining Regions (CDR) HCDR1, HCDR2, HCDR3, wherein HCDR comprises 0-1 substitution; (b) an IgG class light chain comprising an IgG class light chain variable region (VL), comprising LCDR1, LCDR2, LCDR3, wherein LCDR comprises 0-1 substitution; and (c) a mutated Interleukin 2 (IL2) molecule engrafted into HCDR1, wherein the mutated IL2 molecule comprises mutations that reduce affinity of the mutated IL2 molecule for a high-affinity IL2 receptor.SELECTED DRAWING: None

The invention relates to the technical field of biomedicine, in particular to an anti-human immunodeficiency virus type 1 p24 and type 2 p26 antibody and application thereof. The invention provides an antibody or an antigen-binding fragment thereof capable of specifically binding to a p24 protein of human immunodeficiency virus type 1 and a p26 protein of human immunodeficiency virus type 2, and also provides a combination of antibody pairs, a kit and related applications. When the antibody pair is used for immunodetection, antigens of HIV-1 type p24 and HIV-2 type p26 can be detected at the same time, and the antibody pair has the advantage of lower concentration detection limit.

Anti-nicotinamide phosphoribosyltransferase (NAMPT) antibodies or antigen-binding fragments thereof and methods of treating subjects with (NAMPT)-associated local and / or systemic inflammatory disorders are described.

The present invention relates to antibody-based molecules, including full-length antibodies, antigen-binding domains thereof, and antibody derivatives, that can bind to and activate human muscle-specific tyrosine protein kinase (MuSK). The invention further discloses methods of treating neuromuscular conditions using said MuSK antibodies.

The invention relates to an antibody specifically binding to TROP2 or an antigen binding fragment thereof. The invention also encompasses VHH antibodies or heavy chain antibodies that specifically bind to PD-L1. The invention further relates to a bispecific antibody which is constructed on the basis of the TROP2 antibody and the PD-L1 antibody and is specifically combined with the TROP2 and the PD-L1. The invention also encompasses immunoconjugates constructed based on the antibody molecules, such as antibody-conjugated drugs such as ADC. The invention further relates to a preparation method and application of the antibody molecule and the TROP2xPD-L1 targeting bispecific antibody coupling medicine.

Provided herein are novel anti-CD27 and anti-PD-L1 antibodies, and binding domains thereof, as well as bispecific constructs and anti-CD27 binding domain linked to an anti-PD-L1 binding domain. Also provided herein are methods of stimulating T cell activity, methods of inducing or enhancing an immune response, and methods of treating a disease or condition (e.g., cancer) by administering the bispecific constructs, antibodies, or antigen binding fragments thereof, or compositions described herein to a patient in need thereof.

Provided herein are multispecific antigen-binding polypeptide constructs comprising at least two different heterodimers, each comprising a heavy chain and a light chain. At least one heterodimer comprises a Fab region comprising a lambda light chain and at least one heterodimer comprises a Fab region comprising a kappa light chain. One or more of the immunoglobulin heavy and light chains that form the antigen-binding polypeptide construct comprise amino acid modifications that promote correct pairing between the heavy and light chains to form the desired multispecific antigen-binding polypeptide construct. The amino acid modifications may be in the CH1 and / or CL domains, in the VH and / or VL domains, or a combination thereof.

Provided are a B7-H3 binding molecule, an EGFR binding molecule, a B7-H3 / EGFR binding molecule, methods for treating cancers by using the binding molecules, and related pharmaceutical uses thereof.

The present disclosure generally relates to immunoglobulin-related compositions (e.g., antibodies or antigen-binding fragments thereof) capable of binding to the CD33 protein. The antibodies of the present technology are useful in methods for detecting and treating Alzheimer's disease or CD33-associated cancers in subjects in need thereof.

The present invention generally relates to antibodies that bind to CD3, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.